Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Friday as it is currently trading at $81.78, above its previous 52-week high of $81 with 393,372 shares traded as of 10:05 a.m. ET. Average volume has been 1.7 million shares over the past 30 days.
Watson has a market cap of $10.08 billion and is part of the
industry. Shares are up 30.9% year to date as of the close of trading on Thursday.
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. The company has a P/E ratio of 24.5, below the average drugs industry P/E ratio of 64.2 and above the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
TheStreet Ratings rates Watson as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full
52-week high stocks
or get investment ideas from our